ArticleTranslational cancer research2025
Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening air pollutants-related genes to construct a prognostic risk model for lung adenocarcinoma and analyzing its immune microenvironment.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bufalin has shown potential in overcoming cancer resistance to osimertinib and sorafenib in epidermal growth factor receptor ( Methods: The cell experiments including the MTT assay, flow cytometry, and real-time polymerase chain reaction (RT-PCR) were used to determine the effects of bufalin and/or EGFR-TKIs gefitinib on the growth, proliferation, cycle, apoptosis, and expressions of genes linked to the EGFR-phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)-mammalian target of rapamycin (mTOR) signal pathway of human non-small cell lung cancer cell line H1975. In animal experiments, a model of H1975 cell subcutaneous graft tumor in severe combined immune deficiency (SCID) mice was created. Then bufalin and gefitinib were administered for three weeks by gavage and intraperitoneal injection, respectively. Tumor weight, volume, and other indicators were analyzed. In the meantime, RT-PCR and immunohistochemistry were performed to quantify key genes and proteins that were related to the EGFR-PI3K/Akt-mTOR signal pathway, including EGFR, PI3K, Akt, mTOR, 70 kDa ribosomal protein S6 kinase (p70S6K), and eukaryotic translation initiation factor 4E-binding protein (4E-BP) in tumor tissues of various intervention groups. Results: Bufalin and gefitinib could control the cell cycle, induce apoptosis, and impede H1975 cell development and growth. Furthermore, bufalin and gefitinib inhibited the growth of lung cancer tumor and decreased the expression of proteins pertinent to the EGFR-PI3K/Akt-mTOR pathway, including EGFR, Akt, mTOR, and p70S6K. These effects were more pronounced in the combined intervention group. Conclusions: Bufalin can overcome gefitinib resistance in lung cancer by modulating the EGFR-PI3K/Akt-mTOR signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.